



10-10-02

Handwritten notes:
RCE
10/17/02
Ed. of the...
Reg. for RCE

K&K FORM 24(00)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

REQUEST FOR CONTINUED EXAMINATION (RCE)
TRANSMITTAL FORM (37 C.F.R. § 1.114)

DOCKET NO. 11658/10	APPLICATION SERIAL NO. 09/338,221	EXAMINER Anish GUPTA	ART UNIT 1653
------------------------	--------------------------------------	-------------------------	------------------

INVENTOR(S):

Eli PINES and William J. WHITE

RECEIVED

Address to:
Commissioner for Patents
Washington, DC 20231
Box: RCE

OCT 15 2002
TECH CENTER 1600/2900

This is a **request for continued examination** under 37 C.F.R. § 1.114 (RCE) of pending application Serial No. 09/338,221, filed on June 22, 1999, entitled **THERAPEUTIC FIBRINOGEN COMPOSITIONS**

The following constitute the submission **required** by 37 C.F.R. § 1.114(a) and is attached:

- ☒ X Amendment Under 37 CFR 1.116 filed June 28, 2002, copy attached.
☐ Information Disclosure Statement
☐ Drawing Changes
☐ Other Submission: _____

1. The filing fee for this RCE and the required amendment/submission is calculated below. The fee below is calculated based on the status of the claims after the entry of the attached amendment/submission. The fee for any new additional claims is included with this RCE, the fee for previously entered additional claims having already been paid.

	CLAIMS ADDED BY AMENDMENT	MINUS	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA*	RATE (\$) PER CLAIM	FEE (\$)
BASIC FEE						740.00
TOTAL CLAIMS	18		34	0	18.00	0.00
INDEPENDENT CLAIMS	5		5	0	80.00	0.00
MULTIPLE DEPENDENT CLAIM					270.00	
				Number extra must be zero or larger	TOTAL	740.00
	If Applicant is a small entity under 37 C.F.R. §§ 1.9 and 1.27, then divide total fee by 2, and enter amount here.					SMALL ENTITY TOTAL 370.00

10/11/2002 AMUNDAF1 00000165 110600 09338221

01 FC:278 0897 370.00 CH
02 FC:217 460.00 CH

2. Please charge the required RCE and submission filing fee of \$ 370.00 to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
3. Applicants respectfully request a three-month extension of time in which to file a response to the Office Action mailed April 10, 2002, for which a response period expiring on July 10, 2002 was set. The extended period expires on October 10, 2002. Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(a) extension fee of \$460.00 to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
4. The Commissioner is hereby authorized to charge payment of any additional fees required with this communication or arising during the pendency of this application, or to credit any overpayment, to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
5. A duplicate copy of this transmittal form is enclosed.

Respectfully submitted,

KENYON & KENYON

Dated: October 9, 2002

By: Donna M. Praiss by Christine M. Wikes
Donna M. Praiss
(Reg. No. 34,232) Reg. No. 37,967

One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



RECEIVED
OCT 15 2002
TECH CENTER 1600/29
PATENT
11658/10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pines et al.)
Serial No.: 09/338,221)
For: THERAPEUTIC FIBRINOGEN)
COMPOSITION)
Filed: June 22, 1999)

Group Art Unit: 1653
Examiner: A. Gupta

Commissioner for Patents
Washington, D.C. 20231
Box AF

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on:

Date: June 10, 2002

Christine M. Wilkes
Christine M. Wilkes (Reg. No. 37,967)

AMENDMENT

SIR:

Please amend the above-identified patent application as follows:

In the Claims:

Please amend claims 1, 2 and 13, and cancel non-elected claims 18-25 and 27-34 as follows:

Q1
Def 5/17

1. (Amended) A therapeutic composition effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian, clottable fibrinogen recovered from a process comprising precipitating fibrinogen from a sample of non-human, mammalian blood plasma with polyethylene glycol 1000 and